Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12609000238279
Ethics application status
Approved
Date submitted
22/01/2009
Date registered
11/05/2009
Date last updated
2/11/2015
Type of registration
Retrospectively registered
Titles & IDs
Public title
Omega-3 oil and bone health
Query!
Scientific title
Plant-based omega-3 fatty acid supplementation, acceptability and efficacy for bone health
Query!
Secondary ID [1]
287764
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Osteopenia
4223
0
Query!
Condition category
Condition code
Musculoskeletal
4442
4442
0
0
Query!
Osteoporosis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
1 year of oral docosohexanoic acid (DHA) 400 mg daily. DHA is of algal origin (i.e. suitable for vegetarians/vegans). All participants will receive oral vitamin D3 1000 IU daily with calcium carbonate 1200 mg daily
Query!
Intervention code [1]
3941
0
Treatment: Drugs
Query!
Comparator / control treatment
Oral calcium carbonate 1200 mg with vitamin D3 1000 units daily for 1 year. All participants receive this. Particpants in the placebo group will receive corn oil capsules orally daily for 1 year.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
5487
0
Bone mineral density (BMD) as measured by Dual Energy X-ray Absorptiometry (DEXA) at entry into study and after 1 year of participation. DEXA is measured by a form of x-ray machine which uses software to compare absorption of 2 different energies of radiation, thus deriving a Bone Mineral Density value in g/cm2
Query!
Assessment method [1]
5487
0
Query!
Timepoint [1]
5487
0
1 year from commencement of treatment
Query!
Primary outcome [2]
5488
0
change in bone turnover markers as measured by serum N-terminal collagen telopeptide (CTX)
Query!
Assessment method [2]
5488
0
Query!
Timepoint [2]
5488
0
1 year from commencement of treatment
Query!
Secondary outcome [1]
9242
0
None
Query!
Assessment method [1]
9242
0
Query!
Timepoint [1]
9242
0
not applicable
Query!
Eligibility
Key inclusion criteria
DEXA BMD T-score between -1.0 and -2.4 (inclusive)
abbreviations as noted above: Bone Mineral density (BMD); Dual Energy X-ray Absorptiometry (DEXA)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
already on antiresorptive agents
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Recruitment through a DEXA bone mineral density testing service. Potential participants with osteopenic BMD values offered information about participation. Participants randomised to treatment (DHA, Ca, vit D) or control (placebo, Ca, vit D). Allocation is concealed by use of numbered containers. An on-site, third party used a random number generator to allocate numbers to either the active or comparator group.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Random number generator (computerised sequence generation) used to allocate participants to either
(a) Calcium, vitamin D plus placebo (corn oil capsules); or
(b) Calcium, vitamin D plus DHA
There is no stratification.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/02/2009
Query!
Actual
1/12/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
1/10/2009
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
40
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
4570
0
Charities/Societies/Foundations
Query!
Name [1]
4570
0
The Royal Australian College of General Practitioners (RACGP)
Query!
Address [1]
4570
0
RACGP College House
1 Palmerston Crescent
SOUTH MELBOURNE VIC 3205
Query!
Country [1]
4570
0
Australia
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
The Royal Australian College of General Practitioners (RACGP)
Query!
Address
RACGP College House
1 Palmerston Crescent
SOUTH MELBOURNE VIC 3205
Query!
Country
Australia
Query!
Secondary sponsor category [1]
4123
0
Commercial sector/Industry
Query!
Name [1]
4123
0
Martek Biosciences
Query!
Address [1]
4123
0
6480 Dobbin Road,
Columbia, MD 21045
Query!
Country [1]
4123
0
United States of America
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
6620
0
University of Adelaide Human Research Ethics Committee
Query!
Ethics committee address [1]
6620
0
Research Branch THE UNIVERSITY OF ADELAIDE SA 5005
Query!
Ethics committee country [1]
6620
0
Australia
Query!
Date submitted for ethics approval [1]
6620
0
Query!
Approval date [1]
6620
0
26/03/2008
Query!
Ethics approval number [1]
6620
0
H-017-2008
Query!
Summary
Brief summary
Omega-3 oils are known to have benefits for joints, skin and the circulation. There are reasons to believe that they may help improve bone health in people with low bone density. This study aims to examine the safety, effectiveness and acceptability of an omega-3 oil, docosohexanoic acid (DHA) when given for 1 year in combination with calcium and vitamin D.
Query!
Trial website
None
Query!
Trial related presentations / publications
N/A
Query!
Public notes
Query!
Contacts
Principal investigator
Name
29208
0
Dr Simon Vanlint
Query!
Address
29208
0
Discipline of General Practice
University of Adelaide SA 5005
Query!
Country
29208
0
Australia
Query!
Phone
29208
0
+61883134634
Query!
Fax
29208
0
Query!
Email
29208
0
[email protected]
Query!
Contact person for public queries
Name
12455
0
Dr Simon Vanlint
Query!
Address
12455
0
Discipline of General Practice
University of Adelaide SA 5005
Query!
Country
12455
0
Australia
Query!
Phone
12455
0
+61883134634
Query!
Fax
12455
0
Query!
Email
12455
0
[email protected]
Query!
Contact person for scientific queries
Name
3383
0
Dr Simon Vanlint
Query!
Address
3383
0
Discipline of General Practice
University of Adelaide SA 5005
Query!
Country
3383
0
Australia
Query!
Phone
3383
0
+61 8 83034634
Query!
Fax
3383
0
Query!
Email
3383
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF